Short UVA-irradiation of carboplatin (30 min) resulted in 74% mono-functional learn more DNA adducts while prolonged irradiation for four hours converted all mono adducts to bi-functional adducts . Platinum drugs cisplatin, carboplatin and oxaliplatin are currently successful for treating some types of cancer, but have problems associated with toxic side-effects, the development of resistance and lack of tumour selectivity. Promising current work shows that these problems can be overcome to some extent by improved delivery and targeting. For example, platinum complexes can be encapsulated in nanotubes, liposomes, biodegradable proteins and other polymers
and attached to the surfaces of nanotubes, nanorods and other nanoparticles. Encapsulation can be accompanied by wrapping and capping. One advantage of using carriers is that they can be multifunctional, containing not only the Pt drug or prodrug but also targeting molecules such
as cell-penetrating peptides, aptamers, antibodies and various overexpressed receptors. Some nanoparticles can also be made magnetic or can be activated thermally. Encapsulation can also protect reactive platinum complexes from activation before they reach the target site. Initial data indicate that such polymer and nanoparticle supports can be well-tolerated by cells. The preparation (homogeneity) and characterisation of such multi-functionalised platinated systems, which unlike small Pt complexes cannot Compound Library high throughput be crystallised, presents a challenge for translation into the clinical use. Targeting by spatially directed activation of photoactivatable PtIV prodrugs using light is also a promising way of avoiding damage to non-tumour tissue. Moreover, it is evident that these new designs of transport and delivery systems for Pt prodrugs can lead to
the release of novel species which can kill cancer cells by new mechanisms, itself a potentially useful way of combating resistance and extending the spectrum of anticancer activity. Papers of particular interest, published within the period of review, have been highlighted as: • of special interest P.J. Sadler has ownership interest by patent application GB0120618. Rho We thank the ERC (award no. 247450), EPSRC (EP/G006792/1) and Science City (AWM/ERDF) for support, our collaborators and the members of EC COST CM1105 for stimulating discussions. “
“Current Opinion in Chemical Biology 2013, 17:841–846 This review comes from a themed issue Analytical techniques Edited by Milos V Novotny and Robert T Kennedy For a complete overview see the Issue and the Editorial Available online 9th July 2013 1367-5931/$ – see front matter, © 2013 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.cbpa.2013.06.015 Metabolomics is concerned with the comprehensive analysis of low-molecular weight compounds in biological samples such as cells, body fluids and tissues [1 and 2].